Prostate cancer is the most prevalent cancer and the second leading cause of cancer-related deaths among men in the United States. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of the disease, characterized by the failure of androgen-deprivation therapies and a low survival rate. Recently, the prostate-specific membrane antigen (PSMA) has been identified as a tumor antigen in prostate cancer, showing high expression in tumors and low expression in normal tissues. Ambrx has developed ARX517, an engineered precision biologic (EPB) that utilizes an expanded genetic code. ARX517 is an anti-PSMA targeted next-generation antibody drug conjugate (ADC) designed for the treatment of mCRPC patients. It consists of a humanized anti-PSMA antibody that is specifically conjugated to the drug linker AS269, a potent tubulin inhibitor. This results in a drug-to-antibody ratio of 2. Once ARX517 binds to PSMA on the surface of tumor cells, it is internalized and releases a cytotoxic payload that inhibits tubulin polymerization and induces cellular apoptosis.